AMGN Data Bodes Well For Alder BioPharma (ALDR) - Jefferies
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Jefferies analyst, Brian Abrahams, reiterated his Buy on Alder Biopharm (NASDAQ: ALDR) on the heels of Amgen's (NASDAQ: AMGN) impressive patient-reported outcome data. The data was presented at EHMTIC for AMGN's CGRP antibody and supports the likelihood that the CGRP class, including ALDR's ALD403, will show clear QOL improvements and med reductions that ultimately support solid pricing. The analyst believes the favorable risk profile, late stage, and blockbuster market opportunity for '403 remains meaningfully underappreciated in ALDR shares despite the recent runup.
No change to the price target of $62.
Shares of Alder Biopharm closed at $34.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sprint (S) PT Raised to $4.50 at Jefferies
- ARIAD Pharma (ARIA): Cutting PT On Iclusig Pricing - Jefferies
- AK Steel (AKS) PT, Estimates Raised at Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!